Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAPRI Trial With AZD6738 and Olaparib in Recurrent Ovarian Cancer
NCT03462342Phase 2Completed
- Sponsor
- University of Pennsylvania
- Start
- Mar 2018
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ceralasertib in ovarian cancer (5 cohorts), sponsored by University of Pennsylvania. Primary endpoints: Incidence of treatment-emergent adverse events at 2 years, Objective Response Rate at 2 years and 1 more. Started Mar 2018; status: completed.
02
Drugs
ceralasertib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT03462342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03462342.